Aidoc AI vs Komodo Health AI

Enterprise licensing to health systems and radiology groups. No public pricing. FDA-cleared for multiple indications. Contact for pricing.

Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.

Medical image and clinical data processed under HIPAA BAA and applicable healthcare privacy regulations. FDA-cleared for specific clinical indications — review clearance scope for each deployment.

Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.

• ✓Broadest portfolio of FDA-cleared radiology AI algorithms — regulatory clearance required for clinical deployment
• ✓Worklist prioritisation for time-critical conditions (stroke, PE) has direct patient outcome impact
• ✓aiOS platform enables health systems to manage multiple AI algorithms through one integration
• ✓Published clinical evidence from real-world deployments validates outcomes claims

• ✓330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
• ✓Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
• ✓Pulse SaaS interface makes real-world evidence accessible without custom database development
• ✓Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data

• ✕Enterprise health system sales cycles are long and require IT, clinical, and procurement alignment
• ✕FDA clearance is indication-specific — algorithms not cleared for a specific indication cannot be deployed clinically
• ✕Integration with existing PACS and RIS systems requires significant IT implementation effort

• ✕Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
• ✕Real-world data has limitations — claims-based patient identification is less accurate than clinical data
• ✕Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials